''

Article 10 in our Maturity Model series

Executive Summary

The organization domain focuses on the structural elements that support effective clinical trial disclosure. It encompasses roles and responsibilities, cross-functional collaboration, and organizational alignment. A properly coordinated organization ensures efficient disclosure processes, clear accountability, and adaptability to evolving regulatory requirements.


Why this domain matters

A well-structured organizational approach to clinical trial disclosure ensures consistency, efficiency, and compliance across all transparency efforts. Clear roles, responsibilities, and reporting lines enable effective decisionmaking and accountability, reducing the risk of missed deadlines or incomplete disclosures. Strong cross-functional collaboration facilitates the smooth flow of information and expertise among departments, enhancing the quality and timeliness of disclosed data. An optimized organizational structure allows for better resource allocation and scalability, enabling sponsors to adapt to changing regulatory landscapes and growing disclosure requirements. Finally, a mature organizational approach fosters a culture of transparency, aligning disclosure activities with broader corporate values and building trust with patients, healthcare professionals, and regulatory bodies:


Read more

Take the Maturity Model Self-Assessment

This interactive tool will guide you through a comprehensive evaluation of your organization's disclosure practices, enabling you to identify strengths, pinpoint areas for improvement, and chart a clear path toward greater transparency and compliance.

Take our interactive Maturity Model Survey.

About the author

Headshot of Thomas Wicks.

Thomas Wicks

Head of Transparency Operations, Citeline

Thomas Wicks is an experienced strategic leader with over 20 years in life sciences. As Head of Transparency Operations at Citeline, he spearheads strategy for TrialScope's industry-leading disclosure solutions. Thomas is an established thought leader, having spoken at over 60 conferences and authored over 40 publications on disclosure requirements and transparency trends. Thomas is motivated by empowering teams to accelerate solutions that honor trial transparency.

Related resources

Plain Language Summaries Discussion Panel
MAY 23, 2024
Article
薬事規制関連支援サービス

Plain Talk About Plain Language Summaries

Plain language summaries of clinical trial results require a multi-step process: planning, development, translation, and dissemination.

Woman in lab coat holding up test tube in research facility.
JUL 10, 2024
Article
薬事規制関連支援サービス

Clinical Data Transparency a Big Challenge for Smaller Sponsors

Many smaller organizations have not yet implemented a specialized clinical trial disclosure system. Robust transparency, and perhaps even just compliance with multiple regulators, requires commitment from the C-suite for companies of all sizes.

The Clinical Trial Disclosure Maturity Model: a Framework for Excellence
SEP 30, 2024
Article
薬事規制関連支援サービス

The Clinical Trial Disclosure Maturity Model: a Framework for Excellence

The clinical trial disclosure maturity model is a comprehensive framework designed to help organizations assess and improve their disclosure practices.